0000899243-20-019177.txt : 20200715 0000899243-20-019177.hdr.sgml : 20200715 20200715165257 ACCESSION NUMBER: 0000899243-20-019177 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20200715 DATE AS OF CHANGE: 20200715 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: JOHNSON KENNETH ERLAND CENTRAL INDEX KEY: 0001743774 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38536 FILM NUMBER: 201029894 MAIL ADDRESS: STREET 1: C/O XERIS PHARMACEUTICALS, INC. STREET 2: 180 N. LASALLE STREET, SUITE 1800 CITY: CHICAGO STATE: IL ZIP: 60601 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: XERIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001346302 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203352427 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 180 NORTH LASALLE STREET STREET 2: SUITE 1600 CITY: CHICAGO STATE: IL ZIP: 60601 BUSINESS PHONE: 844-445-5704 MAIL ADDRESS: STREET 1: 180 NORTH LASALLE STREET STREET 2: SUITE 1600 CITY: CHICAGO STATE: IL ZIP: 60601 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-06-30 0 0001346302 XERIS PHARMACEUTICALS INC XERS 0001743774 JOHNSON KENNETH ERLAND C/O XERIS PHARMACEUTICALS, INC. 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601 0 1 0 0 See Remarks Common Stock 2020-06-30 5 A 0 E 775 2.26 A 26890 D These shares were purchased due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from January 1, 2020 through June 30, 2020. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2020. Senior Vice President, Clinical Development, Regulatory, Quality Assurance and Medical Affairs /s/ Beth Hecht, as Attorney-in-Fact 2020-07-15